BioCardia Files 8-K: Other Events & Exhibits Noted
Ticker: BCDA · Form: 8-K · Filed: Jul 30, 2024 · CIK: 925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | Jul 30, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, exhibits
Related Tickers: BCDA
TL;DR
BioCardia dropped an 8-K on 7/30 for 'Other Events' & exhibits. No big news yet, just filings.
AI Summary
On July 30, 2024, BioCardia, Inc. filed an 8-K report detailing "Other Events" and "Financial Statements and Exhibits." The filing does not disclose specific financial figures or significant corporate actions but serves as a notification of these items.
Why It Matters
This 8-K filing indicates BioCardia has reported "Other Events" and financial statements, which could contain updates relevant to investors, though specific details are not immediately apparent from the filing's header.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and exhibits, with no immediate indication of significant financial changes or negative developments.
Key Players & Entities
- BioCardia, Inc. (company) — Registrant
- July 30, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-38999 (filing_number) — Commission File Number
FAQ
What specific "Other Events" are being reported by BioCardia, Inc. in this 8-K filing?
The provided filing header does not specify the nature of the "Other Events"; it only lists this as an item being reported.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on July 30, 2024.
What is BioCardia, Inc.'s state of incorporation?
BioCardia, Inc. is incorporated in Delaware.
What is the Commission File Number for BioCardia, Inc.'s 8-K filing?
The Commission File Number for this 8-K filing is 001-38999.
Does this 8-K filing include financial statements?
Yes, the filing lists "Financial Statements and Exhibits" as an item information category.
Filing Stats: 466 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-07-30 07:00:36
Key Financial Figures
- $0.001 B — ch registered Common Stock, par value $0.001 BCDA The Nasdaq Capital Market Warrant
Filing Documents
- bcda20240730_8k.htm (8-K) — 27KB
- ex_705188.htm (EX-99.1) — 9KB
- 0001437749-24-023823.txt ( ) — 183KB
- bcda-20240730.xsd (EX-101.SCH) — 4KB
- bcda-20240730_def.xml (EX-101.DEF) — 13KB
- bcda-20240730_lab.xml (EX-101.LAB) — 17KB
- bcda-20240730_pre.xml (EX-101.PRE) — 13KB
- bcda20240730_8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On July 30, 2024, BioCardia, Inc. (the "Company") issued a press release reporting the submission for 510(k) approval of its patented Morph DNA Steerable Introducer Sheath. This product family is intended to provide a pathway through which medical instruments, such as balloon dilatation catheters, guidewires, or other therapeutic devices, may be introduced into the peripheral vasculature or chambers and coronary vasculature of the heart. A copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 BioCardia, Inc. press release dated July 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: July 30, 2024